Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lexaria BioscienceLEXX -8.02%43 Days Payable is 239.62 as of May. 2026, which is 55% below its 10-year median of 533.17. GuruFocus rates LEXX with a GF Score™ of 43/100 and a GF Value™ of $5.37 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 707 Biotechnology companies, Lexaria Bioscience ranks worse than 141442.57% on this metric.
The historical rank and industry rank for Lexaria Bioscience's Days Payable or its related term are showing as below:
During the past 13 years, Lexaria Bioscience's highest Days Payable was 147399.17. The lowest was 81.59. And the median was 533.17.
LEXX's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 111.24 * Ranked among companies with meaningful Days Payable only.
Lexaria Bioscience's Days Payable
declined
from May. 2025 (5,550.45) to May. 2026 (239.62).
It may suggest that Lexaria Bioscienceaccelerated paying its suppliers.
The historical data trend for Lexaria Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lexaria Bioscience's Days Payable for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a Days Payable of 239.62 as of May. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lexaria Bioscience and its competitors. This is 55% below median its historical median of 533.17. Over the past decade, Lexaria Bioscience's Days Payable has ranged from 81.59 to 147,399.17. According to the industry distribution chart, Lexaria Bioscience ranks #999999 out of 707 companies in the Biotechnology industry.
Is Lexaria Bioscience's Days Payable too high?
Lexaria Bioscience's current Days Payable of 239.62 is 55% below median its 10-year median of 533.17. Over the past 10 years, this metric has ranged from a low of 81.59 to a high of 147,399.17. The Biotechnology industry median Days Payable is 111.24. Lexaria Bioscience's value of 239.62 is 115.4% above this industry median. Based on the distribution chart, Lexaria Bioscience ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Days Payable compare to TPST and LPCN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #999999 out of 707 companies for Days Payable. This places Lexaria Bioscience in the lower half of its industry. The industry median Days Payable is 111.24. Lexaria Bioscience's value of 239.62 is 115.4% above this benchmark. Historically, Lexaria Bioscience's own Days Payable has ranged from 81.59 to 147,399.17 over the past decade. While the company's 10-year median is 533.17 vs. the industry median of 111.24, Lexaria Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current Days Payable of 239.62 is 115.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lexaria Bioscience and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current Days Payable is 239.62, which is 55% below median its own 10-year median of 533.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Possible Value Trap. The stock's GF Value™ is $5.37, compared to a current price of $3.21 — trading 40.2% below its estimated fair value. The current Days Payable is 239.62, which is 55% below median its 10-year median of 533.17 and 115.4% above the Biotechnology industry median of 111.24. Lexaria Bioscience's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Days Payable is 239.62 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued.
The current stock price of $3.21 is trading 40.2% below its estimated GF Value™ of $5.37.
GuruFocus considers Lexaria Bioscience to be Possible Value Trap.
Key valuation signals for LEXX:
Days Payable: 239.62 (55% below median its 10-year median of 533.17)
GF Value™: $5.37 vs. price of $3.21 (40.2% below fair value)
Industry Position: 115.4% above the Biotechnology median (#999999 of 707)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
43GF Score
Get the complete analysis for LEXX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
